Grifois, S.A. (GRFS) Stock Price

GRFSStock
$7.6918.17%52W
Market Cap$5.23B
P/E14.97x
PEG Ratio0.19
Div yield1.92%
Beta0.84

GRFS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-21.48%
Price vs S&P 500 (4W)-2.63%
PEG Ratio0.19
VGM Score57.33
P/E Ratio (Annual)14.97x
Indicated Dividend Yield (Annual)1.92%

GRFS Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2025$0.32$0.26-19.19%(-$0.06)

GRFS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.81
3.81
3.81
3.81

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
GRFSGrifois, S.A.
BCC$7.69
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Grifois, S.A.

Grifols is a global specialty plasma therapeutics company that develops, manufactures, and distributes protein-based medicines for immunological deficiencies, hemophilia, and other chronic and life-threatening conditions. The company's portfolio serves both diagnostic and therapeutic applications across rare and inherited diseases with significant unmet medical needs. Grifols generates the majority of its revenue from the United States market.